2023 World Conference on Lung Cancer (Posters)-P1.25. TARGET: A Phase II Study of 5-year Adjuvant Osimertinib in Completely Resected EGFR-mutated Stage II-IIIB NSCLC

P1.25. TARGET: A Phase II Study of 5-year Adjuvant Osimertinib in Completely Resected EGFR-mutated Stage II-IIIB NSCLC - PDF(Slides)

Back to course

Pdf Summary

The poster presents information about the TARGET study, a Phase II clinical trial investigating the use of adjuvant osimertinib in patients with completely resected EGFR-mutated stage II-III B non-small cell lung cancer (NSCLC). Osimertinib is a drug that blocks mutated EGFR protein on cancer cells, inhibiting their growth and spread. The study aims to determine the efficacy and safety of 5 years of adjuvant osimertinib treatment in these patients.<br /><br />The primary endpoint of the study is investigator-assessed disease-free survival (DFS) at 5 years in patients with common EGFR mutations (exon 19 deletion or L858R). Secondary endpoints include DFS at 3 and 4 years, overall survival (OS) at 3, 4, and 5 years, safety and tolerability, sites of recurrence, and central nervous system (CNS) metastases.<br /><br />Patients eligible for the study must have histologically confirmed non-squamous stage II-III B NSCLC with complete surgical resection and negative margins. They must have EGFR mutations, including common mutations or uncommon mutations (G719X, L861Q, and/or S768I). The maximum interval between surgery and treatment is 10 weeks without adjuvant chemotherapy or 26 weeks with adjuvant chemotherapy.<br /><br />The study is currently ongoing, with the first patient enrolled in March 2023. The primary analysis and study completion are expected in 2029. Data from the study will provide valuable information on the efficacy and safety of adjuvant osimertinib treatment in patients with resected EGFR-mutated NSCLC, including those with uncommon mutations. More information about the study can be found at the provided link.<br /><br />Overall, the study aims to investigate the potential benefits of a longer duration of adjuvant osimertinib treatment and provide insights for clinical decision-making in the management of resectable early-stage EGFR-mutated NSCLC.

Asset Subtitle

Ross Soo

Meta Tag

Speaker Ross Soo

Topic Early-Stage NSCLC: Changing Paradigms & Outcomes

Keywords

TARGET study

Phase II clinical trial

adjuvant osimertinib

EGFR-mutated stage II-III B non-small cell lung cancer

mutated EGFR protein

disease-free survival

overall survival

safety and tolerability

central nervous system metastases

uncommon mutations